Compare Novo Nordisk A/S (NVO) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Workday Inc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Workday Inc trades at $186.59 (market cap $45.26B). The key difference: Novo Nordisk A/S is far larger — about 3.7× Workday Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Workday Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Workday Inc for 38 Days on average.
| NVO | WDAY | |
|---|---|---|
Market Cap | $165.31B | $45.26B |
Volume | 11,432,838 | 2,342,190 |
Sector | Health | Technology |
52-Week High | $63.98 | $245.67 |
52-Week Low | $35.29 | $112.55 |
Typical Hold Time | 116 Days | 38 Days |
Enterprise Value | $179.56B | $45.63B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Workday (WDAY) trades at $187.81, up 1.93% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.75 exceeding the $2.61 forecast. Revenue growth is robust, projected to reach $10.2B in 2026, and the company maintains a high gross profit margin of 75.8%. Recent strategic moves include expansion into the UAE and AI product launches, though layoffs signal operational realignment.
The outlook for WDAY is positive, driven by AI integration and solid financials, but risks include competitive pressures and execution challenges. Analyst consensus is a Buy with a $202.92 price target, suggesting upside potential. Investors should weigh strong profitability against valuation multiples that remain elevated compared to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
